Non-Hodgkin's Lymphoma

Upcoming Educational Forum for Waldenstrom’s Macroglobulinemia Patients and Caregivers (March 9, 2017)

The 22nd Annual IWMF Educational Forum May 19-21, 2017, in Phoenix, Arizona The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led, nonprofit organization... Continue Reading

2016-Year in Review: Advances in Management of Lymphomas (February 16, 2017)

Our understanding of lymphomas has allowed scientists to find new and unique ways of treating this blood cancer. Lymphoma treatments have expanded far beyond chemotherapy, though that type of treatment... Continue Reading

Imbruvica® is approved by FDA for Marginal Zone Lymphoma (February 7, 2017)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan®... Continue Reading

Progress Reported in New Treatments for People with Lymphoma (December 29, 2016)

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, Ph.D., vice president of... Continue Reading

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (December 15, 2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These... Continue Reading

CancerConnect Launches Online Community for Patients Diagnosed with Histiocytosis (June 24, 2016)

Sun Valley ID & Austin TX– OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for adults affected by histiocytosis. This community will provide patients and... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma (June 8, 2016)

A study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL) suggests that  Gazyva® (obinutuzumab) plus chemotherapy... Continue Reading

Novel Immunotherapy Trial for Lymphoma Offers Hope to Patients at Sylvester (May 27, 2016)

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading

Crafting a Better T Cell for Immunotherapy (February 25, 2016)

New technology, not yet tested in humans, aims to reduce patients’ waiting time, increase potency of T-cell therapy T-cell therapy, a form of immunotherapy that uses a patient’s own immune cells to... Continue Reading

CART Therapy Promising in Lymphomas (February 9, 2016)

The use of a patient’s own immune cells to fight cancer through a technique called CART therapy, is proving to be a promising therapeutic approach in the treatment of some lymphomas. These results were... Continue Reading

Revlimid®/Rituxin® Highly Active as Initial Therapy for Mantle Cell Lymphoma (December 10, 2015)

The treatment combination consisting of Revlimid® (lenalidomide) plus Rituxan® (rituximab) provides high rates of long-lasting anti-cancer responses when used as initial therapy for mantle cell lymphoma.... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS